Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AML14 trial of intensive versus non-intensive chemotherapy in older patients with AML or high-risk MDS
ISRCTN62207270Phase 4Completed
- Sponsor
- Blood Cancer UK
- Start
- Dec 1998
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
01
Overview
Phase 4, randomised, open-label trial of daunorubicin, cytarabine, valspodar, hydroxyurea and tretinoin in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) (2 arms), sponsored by Blood Cancer UK. Primary endpoints: Overall survival, Response achievement and 1 more. Started Dec 1998; status: completed.
02
Drugs
daunorubicincytarabinevalspodarhydroxyureatretinoin
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on ISRCTN62207270.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN62207270.